Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (NASDAQ: TIVC) is a pioneering health technology company dedicated to transforming bioelectronic medicine. Our core mission is to develop and commercialize non-invasive products that activate the body’s natural healing mechanisms. Headquartered in San Francisco, Tivic Health is at the forefront of delivering innovative solutions for therapeutic benefit, predominantly focusing on sinus pain relief.
Our flagship product, ClearUP Sinus Relief, is a patented handheld device designed to alleviate sinus pain and congestion using ultra-low electrical currents. This device offers a natural alternative to conventional treatments like nasal sprays, pills, and saline flushes, and is particularly beneficial for individuals suffering from nasal allergies, sinus infections, chronic sinusitis, and the common cold.
Our latest innovation, Synus, provides temporary relief from sinus pain and pressure through microcurrents. This product represents our commitment to offering non-pharmaceutical options to those seeking effective and convenient sinus pain management.
With an emphasis on safety and efficacy, Tivic Health is not only advancing bioelectronic medicine but also setting new standards in patient care. Our team of dedicated professionals continually explores the therapeutic potential of microcurrents, aiming to expand our product line to treat various medical conditions in the future. We are committed to enhancing the quality of life for our users by providing accessible and effective health solutions.
For the latest updates and developments, stay tuned to our Latest News section and follow our progress as we continue to innovate and grow in the exciting field of bioelectronic medicine.
Tivic Health Systems (Nasdaq: TIVC) has enrolled its first subject in an optimization study for their non-invasive vagus nerve stimulation device. The study, conducted by The Feinstein Institute of Bioelectronic Medicine, aims to identify optimal device parameters for influencing autonomic nervous system function. Enrollment is expected to complete by early December.
The global vagus nerve stimulation market is projected to grow from $8.59 billion in 2021 to $21.3 billion in 2030, with a 10.6% CAGR. The peripheral nerve stimulation segment, Tivic's target market, is forecast to grow at 35% CAGR. The company has partnered with Fletcher Spaght Inc. to accelerate product development and commercial strategy based on their successful Phase 1 trial results.
Tivic Health Systems (Nasdaq: TIVC) announced CEO Jennifer Ernst will present at BioFuture 2024 in New York, October 28-30. The presentation, scheduled for October 29 at 2:30 p.m. EDT, will showcase the company's advancements in bioelectronic medicine and recent data on vagus nerve stimulation.
The conference features prominent speakers including Dr. Kevin Tracey from The Feinstein Institutes for Medical Research, Tivic's clinical partners. The event will explore how vagus nerve stimulation is transforming treatments for conditions like rheumatoid arthritis, Crohn's disease, cancer, diabetes, and mental health. One-on-one meetings with investors are available through the BioFuture Showcase Partnering Platform, with a virtual component following November 5-7.
Tivic Health Systems, Inc. (Nasdaq: TIVC) has received approval from The Feinstein Institutes' Institutional Review Board for its non-invasive cervical vagus nerve stimulation (ncVNS) optimization study. This clinical research collaboration aims to refine and optimize stimulation parameters for Tivic Health's ncVNS technology. The study will use physiological measurements to enhance device performance and refine specifications such as electrode positioning and electrical waveform parameters.
Key goals include optimizing treatment strategies and accelerating product development. The study, led by Dr. Theodoros Zanos and Dr. Blake Gurfein, will inform the selection of clinical populations and shape future trial designs. Tivic Health is taking an integrated approach to clinical, product development, and go-to-market planning for its medical-grade non-invasive VNS program, aiming to generate significant new revenue.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has appointed Lisa Wolf as Interim Chief Financial Officer, effective October 1, 2024. Wolf, with 30 years of financial leadership experience, replaces Kimberly Bambach, who will continue as an advisor for strategic transactions and special projects. Wolf has been a senior member of Tivic's finance team for over two years and has contributed to streamlining the company's financial operations. CEO Jennifer Ernst expressed confidence in Wolf's ability to lead Tivic into its next growth phase in bioelectronic therapeutics. The transition aims to maintain continuity while leveraging Wolf's extensive experience in public and private companies across multiple industries.
Tivic Health Systems (NASDAQ: TIVC) reported Q2 2024 financial results and growth strategies focused on vagus nerve stimulation (VNS). Key highlights include:
Financial Performance:
- Q2 2024 revenue: $140,000 (12% decrease YoY)
- H1 2024 revenue: $474,000
- H1 2024 gross margin: 42% (up from 32% in 2023)
- Q2 2024 net loss: $1.3 million (improved from $2.1 million in Q2 2023)
- H1 2024 net loss: $2.7 million ($1.5 million lower than H1 2023)
Business Updates:
- Successful Phase 1 trial of non-invasive VNS approach
- Partnership with Feinstein Institute for VNS optimization
- Launch of ClearUP 2.0
- Exclusive distribution agreement with a top medical equipment distributor
- Cost reduction initiatives, including new manufacturing and logistics arrangements
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine health tech company, has announced its plans to report Q2 2024 financial results and provide a corporate update on August 14, 2024. The company will host a pre-recorded conference call and webcast at 1:30 PM PT / 4:30 PM ET. The update will focus on Tivic's vagus nerve research program and its market potential. Shareholders and interested parties are invited to join the webcast and submit questions by August 11, 2024. The teleconference can be accessed toll-free at 888-506-0062 (US) or 973-528-0011 (International) using the participant access code 316159. A webcast link is also provided for those who prefer to join online.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has announced its 2024 Virtual Annual General Meeting of Shareholders. The meeting is scheduled for Friday, August 9, 2024, at 10:00 a.m. Pacific Time. Stockholders of record as of June 17, 2024, are eligible to attend and vote. The virtual format aims to provide a consistent and convenient experience for all stockholders.
To participate, stockholders will need to use the control number provided on their Notice or proxy card. Beneficial owners without a control number can access the meeting through their brokerage firm's website. The company's Proxy Statement and Annual Report on Form 10-K for 2023 are available on Tivic Health's investor relations website.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has expanded its intellectual property portfolio with three new patents granted in the US and Europe. The patents protect:
1. Adaptive trigger technology for microcurrent stimulation devices
2. Methods to identify preferred treatment points
3. Dynamic adjustment of stimulation voltage during treatment
These innovations enhance device performance, comfort, and user experience. Blake Gurfein, Chief Scientific Officer, emphasized the company's commitment to building a robust IP portfolio for current and future products, including non-invasive vagus nerve stimulation assets.
Tivic Health has appointed Christina Valauri to its board of directors, effective July 1, 2024. Valauri, who has been a strategic advisor to the company since April 2023, brings over 30 years of capital markets experience. She has held leadership roles at Cantor Fitzgerald, Credit Lyonnais, ING, and Natixis, and has extensive experience in healthcare equity research. Valauri is expected to enhance Tivic Health's growth and governance, particularly in bioelectronic medicine. Additionally, Karen Drexler resigned from the board effective September 30, but will continue as a strategic advisor.
Tivic Health Systems (Nasdaq: TIVC) announced the initiation of the second phase of its clinical work to advance its non-invasive cervical vagus nerve stimulation (ncVNS). This phase involves a collaboration with The Feinstein Institutes for Medical Research at Northwell Health to optimize the ncVNS device for specific clinical indications. A 20-person clinical trial will be conducted, focusing on refining electrode positioning and key electrical waveform parameters. The first phase demonstrated significant changes in biomarkers for the brain, heart, and autonomic nervous system. This next phase aims to tailor the therapy to specific clinical indications and accelerate product development. VNS is a growing market within the $8.3 billion neurostimulation sector, with a projected CAGR of 12.2% from 2023 to 2032.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
What is Tivic Health Systems, Inc.?
What does Tivic Health specialize in?
What is the ClearUP Sinus Relief device?
How does Tivic Health's technology work?
What conditions does ClearUP Sinus Relief treat?
What is Synus?
How is Tivic Health different from pharmaceutical companies?
Where can I learn more about Tivic Health's products?
Why choose Tivic Health products?
What are the future plans for Tivic Health?
